Editas Medicine gets approval for first-in-human trial of EDIT-401

Editas Medicine received approval to initiate the Phase 1/2 Strive trial of EDIT-401 for heterozygous familial hypercholesterolemia and reported durable ~90% LDL-C reductions in preclinical studies.Key Highlights:Original SEC Filing: Editas Medicine, Inc. [ EDIT ] - 8-K - Oct. 08, 2026This is an AI…